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Abstract
Background
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)
statement was published in October 2007 to improve quality of reporting of observational
studies. The aim of this review was to assess the impact of the STROBE statement on
observational study reporting and study design quality in the nephrology literature.
Study Design
Systematic literature review.
Setting & Population
European and North American, Pre-dialysis Chronic Kidney Disease (CKD) cohort studies.
Selection Criteria for Studies
Studies assessing the association between CKD and mortality in the elderly (>65 years)
published from 1st January 2002 to 31st December 2013 were included, following system-
atic searching of MEDLINE & EMBASE.
Predictor
Time period before and after the publication of the STROBE statement.
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Outcome
Quality of study reporting using the STROBE statement and quality of study design using
the Newcastle Ottawa Scale (NOS), Scottish Intercollegiate Guidelines Network (SIGN)
and Critical Appraisal Skills Programme (CASP) tools.
Results
37 papers (11 Pre & 26 Post STROBE) were identified from 3621 potential articles. Only
four of the 22 STROBE items and their sub-criteria (objectives reporting, choice of quantita-
tive groups and description of and carrying out sensitivity analysis) showed improvements,
with the majority of items showing little change between the period before and after publica-
tion of the STROBE statement. Pre- and post-period analysis revealed a Manuscript
STROBE score increase (median score 77.8% (Inter-quartile range [IQR], 64.7–82.0) vs
83% (IQR, 78.4–84.9, p = 0.05). There was no change in quality of study design with identi-
cal median scores in the two periods for NOS (Manuscript NOS score 88.9), SIGN (Manu-
script SIGN score 83.3) and CASP (Manuscript CASP score 91.7) tools.
Limitations
Only 37 Studies from Europe and North America were included from one medical specialty.
Assessment of study design largely reliant on good reporting.
Conclusions
This study highlights continuing deficiencies in the reporting of STROBE items and their
sub-criteria in cohort studies in nephrology. There was weak evidence of improvement in
the overall reporting quality, with no improvement in methodological quality of CKD cohort
studies between the period before and after publication of the STROBE statement.
Introduction
Chronic kidney disease (CKD) is a complex chronic condition, and in recent years has emerged
as a major public health problem[1, 2]. CKD has been termed a “Geriatric Giant”, as this dis-
proportionately affects the elderly and is assuming epidemic proportions. Also with increasing
life expectancy, patients are surviving longer with chronic conditions including CKD [3]. With
the increasing burden of CKD, research of treatments developed to improve morbidity and
mortality is vital [4]. Randomised controlled trials (RCTs) indisputably hold many advantages
over observational studies, but owing to ethical or other considerations, may be difficult or
impossible to undertake[5–7]. In nephrology there has not only been a lack of RCTs, but a
large proportion of these RCTs have had negative or null findings[6]. Observational studies
can provide extremely valuable additional evidence, and when rigorously undertaken may
yield similar results as RCTs at far lower expense[8–11].
Standardized reporting of cohort studies is crucial for the evaluation of the merits and flaws
of observational research. Inadequate reporting is associated with potentially biased estimates
of treatment effects and limits the assessment of a study’s strengths, weaknesses and generaliz-
ability[12]. In order to address this, the STrengthening the Reporting of OBservational Studies
in Epidemiology (STROBE) initiative developed recommendations on what should be
Reporting of Cohort Studies Before and After STROBE
PLOSONE | DOI:10.1371/journal.pone.0155078 May 11, 2016 2 / 16
Additionally, this article was co-written by V.S.S and
K.J.J on behalf of the ERA-EDTA Registry which is
an official body of the ERA-EDTA. The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
incorporated in a precise and thorough report of an observational study. The STROBE state-
ment and checklist were published in October 2007[13, 14]. These reporting guidelines were
envisioned to make issues such as confounding, bias, and generalizability more ostensible. In
the long term, this would improve the methodology of studies by increased awareness of these
issues for researchers designing a new study[15, 16].
The scientific value and reliability of the conclusions drawn from a study are determined to
a major extent by the quality of the study design[17]. A variety of tools currently exist to assess
the risk of bias (methodological quality) of observational studies, and are employed when
undertaking a systematic review. These include quality scales, simple checklists, or checklists
with a summary judgment for assessment of the risk of bias[18].
The objectives of this review were (a) to determine whether the publication of the STROBE
statement is associated with an improvement in the reporting quality of cohort studies assess-
ing mortality in elderly patients with CKD; and (b) to determine whether the publication of the
STROBE statement is associated with a decrease in risk of bias (improvement in the methodo-
logical quality) of cohort studies assessing mortality in elderly patients with CKD.
Materials and Methods
Data selection
A systematic literature search was performed in Medline and Embase using the OvidSP inter-
face to identify all papers describing pre-dialysis CKD cohort studies in the elderly (> 65 years)
where mortality was reported as an outcome. This systematic review was conducted a part of
the background preparation for the EQUAL study which is an international (European) multi-
centre prospective observational cohort study looking at the timing of the start of dialysis in
elderly patients (65 years) with estimated glomerular filtration rate (eGFR) of 20mls/min
and therefore the review is restricted to CKD cohort studies in the elderly[19]. The search
query is presented in Item A in S1 File (available as online supplementary material).
Papers published between 1st January 2002 and 31st December 2013 were included, as the
KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification,
and Stratification were published in 2002[20]. Only articles published in English were consid-
ered for the purposes of the review. The initial search strategy yielded more than 10,000 hits,
hence the number of studies were reduced by restricting the search to European and North
American studies. Each article was double sifted at title, abstract and full text stage using prede-
fined study inclusion and exclusion criteria. Any disagreements about inclusion were resolved
by discussion.
The systematic review aimed to cover reporting and design of observational studies before
and after the publication of the STROBE statement which was published in October 2007. We
assessed reporting and methodological quality during two time periods: before STROBE
between 1/1/2002-31/12/2007 and after STROBE 1/10/2008-31/12/2013, allowing a one-year
run-in period. By excluding publications in the immediate twelve months post-STROBE we
allowed a period of one year for submission, revision and publication of research adhering to
the new guidelines.
Data extraction
The reporting of the selected studies was assessed using the STROBE checklist itself, and the
methodological quality assessed using three tools. Thirteen of the 22 STROBE checklist items
were assessed with 2 to 6 questions per item generating 55 questions. The STROBE checklist is
presented in Table A in S1 File (available as online supplementary material). These could be
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answered as “yes,” “partly,” “no,” “unclear,” or “not applicable”. We used similar methodology
to that reported in the publication by Langan et al[21].
To assess methodological quality, the articles were scored on the Newcastle Ottawa Scale
(NOS). At the time this study was designed NOS was recommended by Cochrane for evaluat-
ing the risk of bias in observational studies for inclusion in systematic reviews [22, 23]. The
articles were also scored using the Scottish Intercollegiate Guidelines Network (SIGN) checklist
for cohort studies[24], and Critical Appraisal Skills Programme (CASP) cohort studies check-
list[25] to estimate concurrent validity of NOS tool. These three checklists were chosen because
they were simple checklists without an additional summary judgement[26].
The eligible papers that were identified by the sifting process were each scored using the
STROBE, NOS, SIGN and CASP checklists by two reviewers. Where there was disagreement
between reviewers, consensus was reached by discussion.
Outcome measure
Quality of study reporting was calculated by specific STROBE items and at a manuscript level.
A STROBE question score (SQS) was calculated; the number of publications in a period that
adequately reported a question divided by the number of publications in which this question
was applicable, expressed as a percentage (item analysis). A Manuscript STROBE score (MSS)
was calculated for every manuscript; the number of questions (maximum of 55 questions) ade-
quately reported in the publication divided by the number of applicable questions, expressed as
a percentage (manuscript analysis).
Similarly, to assess the quality of study design the manuscript NOS score (MNOS), manu-
script SIGN score (MSiS) and manuscript CASP score (MCAS) were calculated; the number of
questions adequately addressed (in each appraisal tool) divided by the number of applicable
items, expressed as a percentage in order to facilitate comparison.
Data Analysis
Comparison between pre and post-period SQS was performed by calculating the risk (propor-
tion) difference between the two groups using the Wald test and respective 95% confidence
intervals, with Benjamini and Hochberg adjusted p values (False Discovery Rate) to control for
multiple testing[27]. MSS, MNOS, MSiS and MCAS were reported as a median with respective
interquartile range (IQR). Pre- and post-period median MSS, MNOS, MSiS and MCAS were
compared using the Mann-Whitney (MW) test. Despite excluding articles published for a
period of 1 year after introduction of STROBE, this could potentially have been insufficient for
uptake and penetration of new information. Therefore a spline linear regression model was
used to determine the impact of STROBE over time[28]. Sub-group analyses of MSS were car-
ried out restricting articles to those published in nephrology journals, STROBE endorsing and
non-endorsing journals and by journal impact factor in the year that the article was published.
Sensitivity analyses were carried out by excluding the outlying MSS if any data points were less
than 1.5 interquartile ranges (IQRs) below the first quartile or above the third quartile (< Q1–
1.5×IQR or> Q3 + 1.5×IQR). Simple and weighted kappa statistics were used to compare
agreement between reviewers for the NOS, SIGN and CASP checklists. All tests were two-
tailed, and p values,< 0.05 were considered statistically significant. Data were analysed using
STATA v13.1 (College Station, TX, USA) and SAS v9.3 (SAS Institute, Cary, NC, USA)
software.
Reporting
The study has been reported in accordance with PRISMA reporting guidelines.
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Results
Reporting Quality
Fig 1 shows the flow diagram of exclusions. Of the 3621 articles initially identified by the Med-
line and Embase search, 3584 (98.9%) were excluded after the sifting process (Fig 1). Only 37
articles met the pre-defined selection criteria for the scoring stage of the review during the
inclusion period. Of these 37 articles, 11 were in the pre-STROBE era (1/1/2002-31/12/2007) &
Fig 1. PRISMA flow diagram.
doi:10.1371/journal.pone.0155078.g001
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26 in the post-STROBE period (1/10/2008-31/12/2013). Twenty-two of these articles were pub-
lished in nephrology and 15 in other medical journals. The list of articles considered at the
scoring stage of the study is provided in Item B in S1 File (available as online supplementary
material).
Table 1 summarises the STROBE, NOS, SIGN and CASP scores for each of the articles in
the pre and post-STROBE period. In most cases, reporting quality (STROBE) and methodolog-
ical quality (NOS, SIGN and CASP) correlated well. However, in some articles methodological
quality scored highly with a low score for reporting and vice versa.
Some of the STROBE question scores showed a ceiling effect as they were already at a maxi-
mum level in the pre-STROBE period and could therefore only remain static or decline. Others
saw improvements over the period such as “choice of quantitative groups” (30% vs 71%,
p = 0.02), “addressing of losses to follow up” (0% vs 36%, p< 0.001), “description of and carry-
ing out sensitivity analysis” (18% vs 58%, p = 0.01 & 18% vs 65%, p = 0.002) and “usage of flow
diagram” (0% vs 19%, p = 0.01). However, after adjusting for multiple testing, the change in
only two items’ scores remained unlikely to be due to chance; “addressing of losses to follow
up” (p = 0.02) and “carrying out sensitivity analysis” (p = 0.04). The majority of STROBE ques-
tions showed little improvement between the two periods. Some critical questions, such as
hypothesis specification and those important to interpretation of study validity such as sample
size estimation, addressing missing data, addressing loss to follow up, reason for non-participa-
tion and usage of flow diagram continue to be under reported with less than 50% reporting
these items in both periods. Details regarding the reporting of the 55 STROBE items in the 37
included cohort studies are shown in Table 2.
Pre- and post-period analyses revealed an increase in MSS (median score 77.8 (IQR, 64.7–
82.0) vs 83 (IQR, 78.4–84.9), p = 0.04) (see Table 3). Any pre-STROBE period articles with
MSS scores less than 47.4 and post-STROBE period less than 69 were considered to be outliers.
Excluding outliers, the improvement in the MSS between the two periods showed a stronger
statistical relationship (p = 0.01). The results were essentially unchanged when restricted to
nephrology journals or stratified by STROBE endorsing or non-endorsing journals, though
there was less statistical power to test for differences. Journals with impact factor< 5 saw
greater change over the two periods when compared to journals with impact factor 5 but
given the overlap in the confidence intervals this may have occurred by chance.
Time series analysis of MSS showed that there was a significant improvement in the quality
of reporting in the latter three years (1/1/11 to 31/12/13) when compared to the first three
years (1/10/2008 to 31/12/2010) after the introduction of the STROBE statement (Table 4).
Longitudinal analysis of the MSS using a spline linear regression model (Fig 2), having
excluded outliers, suggested a turning point in 2008 with a slight negative trend in the pre-
STROBE period (coefficient—0.06, SE 0.11) and a positive slope in the post-STROBE period
(coefficient 0.21 SE 0.05) but this may have occurred by chance (Slope change coefficient 0.27,
SE 0.16; p value = 0.10).
Methodological quality (study design); comparison in the pre- and post-
STROBE period
We found no evidence for any change in the methodological quality of studies in the pre and
post-STROBE period using the Newcastle Ottawa Scale (NOS) (median MNOS 88.9% [IQR,
66.7–100] vs 88.9% [IQR, 88.9–100], p = 0.51), Scottish Intercollegiate Guidelines Network
(SIGN) (median MSiS 83.3% [IQR, 61.5–100] vs 83.3% [IQR, 70–90.9], p = 0.93) and Critical
Appraisal Skills Programme (CASP) (median MCAS 91.7% [IQR, 83.3–100] vs 91.7% [IQR,
83.3–100], p = 0.93) (Fig 3).
Reporting of Cohort Studies Before and After STROBE
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Inter-rater agreement
Agreement between raters for the NOS, SIGN and CASP tools was calculated using the simple
or weighted Kappa coefficient. These were assessed at three levels: raters’ agreement on appli-
cability, clarity (can’t say) and yes/no. The inter-rater agreement for each of the tools was
Table 1. Summary of pre and post-STROBE period Manuscript STROBE score (MSS), Manuscript NOS score (MNOS), Manuscript SIGN score
(MSiS) & Manuscript CASP score (MCAS) by article. The citations for the manuscripts are listed in online supplementary material (Item B in S1 File).
Publication date Journal Study Reporting Study Design
MSS MNOS MSiS MCAS
Pre-STROBE
Dec-02 Journal of American College of Cardiology 76.5 55.6 22.2 33.3
Jun-03 American Journal of Kidney Diseases 77.8 88.9 91.7 100.0
Oct-04 Journal of the American Society of Nephrology 66.7 66.7 50.0 33.3
Apr-05 The Journal of the American Medical Association 88.7 88.9 100.0 100.0
Sep-05 Journal of the American Society of Nephrology 64.7 88.9 80.0 83.3
Dec-05 Journal of the American Society of Nephrology 84.6 66.7 61.5 83.3
Nov-06 British Medical Journal 82.0 100.0 100.0 91.7
Jul-07 Renal Failure 49.1 100.0 88.9 100.0
Jul-07 Journal of the American Society of Nephrology 80.4 100.0 100.0 100.0
Nov-07 Nephrology Dialysis Transplantation 51.1 100.0 80.0 91.7
Dec-07 Archives of Internal Medicine 77.8 88.9 83.3 91.7
Post-STROBE
Nov-08 Nephrology Dialysis Transplantation 83.0 88.9 83.3 100.0
Dec-08 Nephrology Dialysis Transplantation 84.9 77.8 90.0 83.3
Feb-09 Journal of the American Society of Nephrology 72.9 100.0 83.3 91.7
Apr-09 American Journal of Kidney Diseases 90.0 100.0 69.2 100.0
Jul-09 American Journal of Kidney Diseases 83.7 100.0 100.0 91.7
Jul-09 Clinical Journal of the American Society of Nephrology 75.0 37.5 25.0 33.3
Dec-09 Journal of American Geriatric Society 78.4 100.0 87.5 100.0
Jul-10 Nephrology Dialysis Transplantation 77.6 100.0 90.9 91.7
Oct-10 Journal of Nephrology 39.6 100.0 100.0 100.0
Sep-10 Journal of General Internal Medicine 83.0 77.8 54.5 41.7
Nov-10 Rejuvenation Research 73.6 88.9 80.0 91.7
Sep-11 Clinical Journal of the American Society of Nephrology 92.2 66.7 90.9 75.0
Jan-12 Nefrologia 50.0 77.8 90.9 91.7
Feb-12 Age and Ageing 83.0 100.0 91.7 100.0
Apr-12 Nephrology Dialysis Transplantation 87.8 88.9 91.7 100.0
Apr-12 The American Journal of Medicine 79.6 100.0 83.3 83.3
May-12 Journal of American Geriatric Society 83.0 88.9 91.7 100.0
May-12 Nephrology Dialysis Transplantation 88.0 100.0 66.7 75.0
Jun-12 The Journal of the American Medical Association 84.9 88.9 66.7 66.7
Jun-12 Clinical Journal of the American Society of Nephrology 83.0 88.9 76.9 83.3
Jul-12 Journal of American Geriatric Society 79.6 88.9 100.0 91.7
Dec-12 Family Practice 84.6 77.8 63.6 83.3
Feb-13 American Journal of medicine 83.0 88.9 75.0 100.0
Apr-13 BMC Nephrology 84.6 100.0 70.0 100.0
May-13 BMC Nephrology 83.0 100.0 88.9 83.3
Sep-13 Clinical Journal of the American Society of Nephrology 90.2 100.0 80.0 66.7
doi:10.1371/journal.pone.0155078.t001
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Table 2. Median STROBEQUESTION SCORE (SQS), Difference (95%CI) with p value of the 55 data items (22 items were further sub-divided to 55
questions in total) in 37 CKD cohort studies, by publication period.
Item
number
Data Items Pre-
STROBE
Post-
STROBE
Difference LCI UCI p
value
FDR FDR*
SQS SQS
Title and Abstract
1A Is the design described adequately in the title or abstract? 0.73 0.69 -0.04 -0.35 0.28 0.83 0.91 0.93
1B Does the abstract provide an informative summary of what
was done and found?
1.00 1.00 0.00 - - - - -
Introduction
2 Is the scientiﬁc background and rationale for the
investigation reported?
1.00 1.00 0.00 - - - - -
3A Are any pre speciﬁed hypotheses reported? 0.18 0.23 0.05 -0.23 0.33 0.73 0.91 0.93
3B Are the objectives reported? 0.73 0.96 0.23 -0.04 0.51 0.09 0.62 0.64
Methods
4 Are the key elements (ie, retrospective/prospective, cohort/
cross-sectional) of the study design presented early in the
paper?
1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 .
5A Are the settings reported? 0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74
5B Are the locations reported? 1.00 0.88 -0.12 -0.24 0.01 0.07 0.52 .
5C Are relevant dates including periods of recruitment
reported?
1.00 0.96 -0.04 -0.11 0.04 0.31 0.62 .
5D Are relevant dates including periods of exposure reported? 1.00 0.93 -0.07 -0.21 0.06 0.30 0.62 .
5E Are relevant dates including periods of follow-up reported? 0.91 0.96 0.05 -0.13 0.24 0.58 0.81 0.87
5F Are relevant dates including periods of data collection
reported?
0.73 0.92 0.20 -0.09 0.48 0.17 0.62 0.74
6A Are the eligibility criteria for participants described? 1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 .
6B Are the sources of participants described? 1.00 0.92 -0.08 -0.18 0.03 0.14 0.62 .
6C Are the methods of selection described? 1.00 0.96 -0.04 -0.11 0.04 0.31 0.62 .
6D Are the methods of follow-up described? 0.91 0.96 0.05 -0.13 0.24 0.579 0.81 0.87
6E If it is a matched study, are the matching criteria and the
numbers of exposed and unexposed described?
0.00 1.00 1.00 - - - - -
7A Are all outcomes described if applicable? 0.91 0.96 0.05 -0.13 0.24 0.58 0.81 0.87
7B Are all exposures described if applicable? 1.00 1.00 0.00 - - - - -
7C Are all predictors described if applicable? 0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74
7D Are potential confounders described? 0.91 0.92 0.01 -0.18 0.21 0.89 0.93 0.94
7E Are all effect modiﬁers described? 0.73 0.80 0.07 -0.23 0.38 0.64 0.86 0.91
7F Are diagnostic criteria described if applicable? 0.80 0.92 0.12 -0.15 0.39 0.40 0.73 0.84
8A Are the sources of data and details of methods of
measurement given for each variable of interest?
0.91 0.85 -0.06 -0.28 0.16 0.57 0.81 0.87
8B If there is more than 1 group, are the measurement
methods comparable?
0.75 1.00 0.25 -0.17 0.67 0.25 0.62 0.74
9 Was there any effort to address potential sources of bias? 0.91 0.92 0.01 -0.18 0.21 0.89 0.93 0.94
10 Did they describe how the study size was determined? 0.00 0.04 0.04 -0.04 0.13 0.31 0.62 0.74
11A Did they describe how quantitative variables were handled
in the analysis?
0.80 0.80 0.00 -0.29 0.29 1 1 1
11B Did they describe which groupings were chosen for
quantitative variables?
0.90 0.83 -0.07 -0.31 0.17 0.58 0.81 0.87
11C Did they describe why quantitative groups were chosen? 0.30 0.71 0.41 0.07 0.75 0.02 0.17 0.14
12A Did they describe all statistical methods including those to
deal with confounding?
0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74
12B Did they describe methods to examine subgroups and
interactions?
0.73 0.72 -0.01 -0.32 0.31 0.96 0.98 0.99
12C Did they explain how missing data were addressed? 0.27 0.38 0.11 -0.21 0.43 0.50 0.81 0.87
(Continued)
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Table 2. (Continued)
Item
number
Data Items Pre-
STROBE
Post-
STROBE
Difference LCI UCI p
value
FDR FDR*
SQS SQS
12D Did they explain if applicable how losses to follow-up were
addressed?
0.00 0.36 0.36 0.16 0.56 <0.001 0.02 0.02
12E Did they describe any sensitivity analysis? 0.18 0.58 0.40 0.10 0.69 0.01 0.14 0.12
Results
13A Did they report the numbers of individuals at each stage of
the study numbers potentially eligible, examined for
eligibility, conﬁrmed eligible, included in the study, and
completed follow-up and were analysed?
0.64 0.81 0.17 -0.15 0.49 0.30 0.62 0.74
13B Did they give reasons for nonparticipation at each stage? 0.30 0.48 0.18 -0.18 0.53 0.33 0.64 0.75
13C Did they use a ﬂow diagram if appropriate? 0.00 0.19 0.19 0.04 0.34 0.01 0.15 0.13
14A Did they give the characteristics of study participants (eg,
demographic, clinical, and social) and information on
exposures and potential confounders?
1.00 1.00 0.00 - - - - -
14B Did they indicate the number of participants with missing
data for each variable of interest?
0.27 0.15 -0.12 -0.42 0.18 0.43 0.74 0.85
14C Did they summarize follow-up time (average and total
amount)?
0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.7394
15A Did they report numbers of outcome measures over time? 1.00 1.00 0.00 - - - - -
15B Did they report summary measures over time? 0.82 0.92 0.10 -0.15 0.35 0.41 0.73 0.84
16A Did they give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (eg, 95%
conﬁdence interval)?
0.82 0.92 0.03 -0.24 0.29 0.84 0.91 0.93
16B Did they detail which confounders were adjusted for and
why they were included?
0.90 0.92 0.02 -0.19 0.24 0.83 0.91 0.93
16C Did they report category boundaries when continuous
variables were categorized?
0.90 0.88 -0.03 -0.25 0.20 0.83 0.91 0.93
16D Did they, if relevant, consider translating estimates of
relative risk into absolute risk for a meaningful period?
0.33 0.26 -0.07 -0.43 0.28 0.69 0.90 0.93
17A Did they report on other analyses done, eg, analysis of
subgroups or interactions?
0.64 0.85 0.21 -0.11 0.53 0.19 0.62 0.74
17B Did they do a sensitivity analysis? 0.18 0.65 0.47 0.18 0.76 0.002 0.04 0.03
Discussion
18 Did they summarize key results with reference to study
objectives?
0.82 1.00 0.18 -0.05 0.41 0.12 0.62 0.70
19 Did they discuss the limitations of the study taking into
account potential sources of bias or imprecision (including
discussion of the magnitude of any potential sources of
bias)?
0.91 1.00 0.09 -0.08 0.26 0.29 0.62 0.74
20 Did they give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence?
1.00 1.00 0.00 - - - - -
21 Did they discuss the generalizability (external validity) of
the study results?
0.73 0.76 0.04 -0.27 0.35 0.80 0.91 0.93
Other Information
22A Did they give the source of the funding in the present study
and, if applicable, for the original study on which the
present article is based?
0.73 0.77 0.03 -0.28 0.34 0.84 0.91 0.93
22B Did they give the role of the funders in the present study
and, if applicable, for the original study on which the
present article is based?
0.36 0.46 0.09 -0.25 0.44 0.60 0.81 0.87
* False Discovery Rate (FDR) calculated excluding questions which had 100% completeness in the pre-STROBE phase.
doi:10.1371/journal.pone.0155078.t002
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overall inadequate, with the NOS tool having poor agreement between the three pairs of raters’.
The CASP tool fared slightly better compared to the SIGN tool in raters’ assessment of clarity.
A summary table of Kappa coefficients is included in Table B in S1 File (available as online sup-
plementary material).
Discussion
This systematic review assessed the impact of the publication of the STROBE statement on
quality of study design and reporting of methodology. It showed that, after publication of
STROBE, a large proportion of the STROBE items and sub-criteria continue to be underre-
ported in CKD cohort studies of mortality in elderly patients. Reporting rates were lowest for
hypothesis specification, usage of flow diagrams and addressing missing data. There was evi-
dence of improvement in the reporting quality of CKD cohort studies particularly in the latter
three years of the post-STROBE period, which was also seen when looking at the temporal pat-
terns but this may have occurred by chance. We found no evidence that the quality of study
design as assessed by 3 different tools NOS, SIGN and CASP had improved. However, these
quality assessment tools have poor to moderate inter-rater reliability and might not be suitable
for use without consensus agreement between raters.
The publication of CKD guidelines in 2002 has potentially had an impact on the volume of
CKD research with approximately 2.5 times the number of studies in the post-STROBE period
compared to the pre-STROBE period[20].
Inadequate reporting not only hinders critical assessment by others of the strengths and
weaknesses in study design, conduct, and analysis, it affects judgement of whether and how
results can be included in systematic reviews and also impacts on the reader assessment of the
studies generalizability [29]. Our results are consistent with other studies assessing deficiencies
Table 3. Summary of quality of reporting as assessed using the Manuscript STROBE Score (MSS).
Pre-STROBE Post-STROBE
N median MSS (IQR) N median MSS (IQR) p value
All Journals 11 77.8 (64.7–82.0) 26 83 (78.4–84.9) 0.04
All Journals (excluding outliers) * 11 77.8 (64.7–82.0) 24 83 (79.6–84.9) 0.01
Nephrology Journals 6 72.3 (64.7–80.4) 16 83.4 (76.3–87.9) 0.09
STROBE endorsing Journals (3) 2 79.9 (77.8–82) 3 90 (83.7–90.9) 0.08
Non-STROBE endorsing Journals (13) 9 76.5 (64.7–80.4) 23 83 (77.6–84.6) 0.10
Impact FACTOR < 5 3 51.1 (49.1–77.8) 16 83 (78–84.6) 0.06
Impact FACTOR  5 8 79.1 (71.6–83.3) 10 83.4 (79.6–90.0) 0.13
* Excluding articles that were less than 1.5 interquartile ranges (IQRs) below the ﬁrst quartile (< Q1–1.5×IQR). Pre-STROBE = 47.4 & Post-STROBE = 69
doi:10.1371/journal.pone.0155078.t003
Table 4. Quality of the reporting of observational studies as assessed using the Manuscript STROBE score (MSS) over time.
Pre-STROBE publication Immediate Post-STROBE publication Late Post-STROBE publication p value p value
(period 1) (period 2) (period 3) period period
1/1/2002 to 31/12/2007 1/10/2008 to 31/12/2010 1/1/11 to 31/12/13 1 vs 2 1 vs 3
N 11 10 14
Median MSC 77.8 80.7 83.8 0.23 0.003
IQR 64.7–82.0 75–83.7 83–87.8
doi:10.1371/journal.pone.0155078.t004
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in reporting of individual STROBE items such sample size, use of flow diagram and reporting
of missing data [21, 30–35].
A number of studies, including a Cochrane review, have demonstrated improvements in
reporting quality of randomised control trials (RCTs) after the introduction of the Consolidated
Standards of Reporting Trials (CONSORT) statement with a significant improvement in journals
endorsing this guideline statement[36–40]. An RCT has also shown that using reporting guide-
lines in the peer review process improves the quality of manuscripts[41]. Our study showed
weak evidence of improvement in the quality of reporting of CKD cohort studies over time fol-
lowing the introduction of the STROBE statement. The improvements unfortunately fell short of
the intended expectations when compared to the impact the CONSORT statement had achieved
upon the reporting quality of RCTs. These results were similar to the only other study looking at
quality of reporting, published in the dermatology literature. Those authors attributed the lack of
improvement to the short follow up period after STROBE introduction (2008–10)[30]. However,
in our study the small improvement could be attributable to the fact that the reporting of
nephrology literature in the pre-STROBE period was already of a higher standard (median MSS
77.8 IQR 64.7–82.0) in comparison to dermatology literature (median score 58 IQR 46–73).
Fig 2. Time series of Manuscript STROBE scores (MSS) from spline linear regression models.
doi:10.1371/journal.pone.0155078.g002
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Journal endorsement of reporting guidelines has been shown to improve reporting quality
of manuscripts submitted to journals[41]. Given that only two medical journals (British Medi-
cal Journal & Ageing) and one renal journal (American Journal of Kidney Diseases) included
in this review had endorsed the STROBE statement, any evidence of improvement in reporting
quality of cohort studies in nephrology literature is probably attributable to the penetration of
STROBE statement over time rather than to its endorsement by journals[42]. The lack of
improvement of reporting standards seen in the STROBE endorsing journals is not an indict-
ment of these journals but maybe attributable to the small sample size to accurately test for dif-
ferences between the groups. An important observation that was made during the process of
this review was that despite studies having similar reporting standards, reflected by their simi-
lar MSS, some studies had failed to adequately report essential criteria.
For most of the articles included in this study reporting and methodological quality were
well correlated, however the assessment of the methodological quality of a study is largely
Fig 3. Box plot summarisingmethodological quality of the studies in the Pre and Post-STROBE period as assessed using the NOS,
CASP and SIGN.
doi:10.1371/journal.pone.0155078.g003
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dependent on adequate reporting of the research. Therefore, drawing any inferences about a
study’s design quality is made harder if the reporting quality is inadequate.
One of the main goals of reporting guidelines was to improve reporting clarity and not
necessarily improve the quality of research, but in due course achieve it as an indirect effect.
Due to interchangeable usage of the terminology ‘reporting quality’ and ‘methodological
quality’, the STROBE statement has often been used inappropriately for the assessment of
methodological quality of observational research[16]. There are a number of assessment
tools that have been developed to assess quality and susceptibility to bias in observational
studies with only half of the identified tools have described their development or validity and
reliability [26]. The review by Sanderson et al highlighted the lack of a single obvious tool for
assessing quality of observational epidemiological studies[26]. The bias assessment tools used
in this study (NOS, SIGN and CASP) were subjective, differed by content, format and valid-
ity. The bias assessment tools identified deficiencies in the articles relating to consideration
of participant’s lost to follow up (attrition bias), exposure level or prognostic factor measured
only once (detection bias), and inadequate methods of outcome assessment (detection bias).
However, given that the assessment of methodological quality is largely reliant on the report-
ing of study design, one might therefore fail to detect differences in design quality if reporting
is inadequate. Also given the latency period of designing a new study, undertaking it and
then publishing it, might have been simply too soon for the STROBE statement to have influ-
enced the methodological quality of studies. The NOS tool was previously recommended by
Cochrane for evaluating the risk of bias but published literature has demonstrated poor
inter-rater reliability between individual reviewers[43, 44]. The results of our study are con-
sistent with these findings as all of the three tools (NOS, SIGN and CASP) showed poor
agreement between individual reviewers. The usability of a tool depends on its clarity. More-
over, the tools contain items whose scoring is subjective and dependent on reviewers’ percep-
tions and domain knowledge. Cochrane now recommends the ACROBAT-NRSI bias
assessment tool for non-randomized studies which has been developed by members of the
Cochrane Bias Methods Group and the Cochrane Non-Randomised Studies Methods Group
[45, 46]. However, at the time of drafting this manuscript, this tool remains yet to be tested
for consistency between individual reviewers.
A strategy to improve inter-rater agreement would be tailoring and training of reviewers
prior to implementation of the tools. Due to the poor reliability of the tools demonstrated here,
it should be strongly considered that each study should be assessed by at least two reviewers
prior to inclusion in a systematic review/meta-analysis.
One of the strengths of our study is that we studied the impact of STROBE upon both qual-
ity of reporting and study design. The study has good internal validity as the selection and eval-
uation processes were independently performed by two reviewers. However, as the articles
were included from one field of medicine (CKD) we must be cautious in generalising our find-
ings to other areas. The other limitation of the study was that it only covered articles from
Europe and North America. There was also an imbalance in the number of studies assessed in
the two periods probably due to the KDIGO CKD guidelines which were published in 2002.
This imbalance could have potentially introduced a lack of power to detect difference in qual-
ity. It was also impossible to blind the reviewers to the publication date during the sifting stage
of the review, and the journal name during the review of quality which could have biased the
reviewers’ assessment of quality of the study. Finally, whilst we examined a five-year period
post-STROBE, it is possible that we failed to find any benefit for methodological quality due to
the long latency period between designing a new study, obtaining funding, undertaking data
collection, analysis and publication.
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Conclusion
This study highlights continuing deficiencies in the reporting of observational studies in the
nephrology literature. However, the publication of the STROBE statement may have positively
influenced the quality of some aspects of observational study reporting. There was no evidence,
however, that methodological quality improved over this time period. With continued efforts
from researchers and with particular focus on the domains identified as deficient by the
STROBE statement and bias reporting tools, this presents an opportunity to improve the valid-
ity of observational research in nephrology. With increased awareness by authors and editors
regarding compliance of manuscripts to the STROBE statement and journal endorsement of
the STROBE statement, we hope that not only reporting but also the design of future studies
will be improved.
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